CLX Medical amends purchasing agreement for ThyroTest rapid screening device
Terms of the amendment to the definitive agreement include the issuance to ThyroTec of series C convertible preferred shares of CLX Medical and a note in the amount
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.